FPGT-TNNI3K

Across TCGA pan-cancer cohorts, FPGT-TNNI3K Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FPGT-TNNI3K data layer compared with 19 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FPGT-TNNI3K Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FPGT-TNNI3K expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUSC, and PRAD are the cancer types where FPGT-TNNI3K Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.435	.010	28	view →
LUSC	OS	Median	All	0.378	0.666	.005	19	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.031	6	view →
SKCM	OS	Median	All	0.637	0.794	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FPGT-TNNI3K–UCEC (DFS)

Open the UCEC breakdown →